Eli Lilly and Co
Jim Cramer says GE Healthcare’s unwarranted post-earnings plunge is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) April showers : The Dow Jones […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Stocks producing the most important moves midday: Eli Lilly, 3M, PayPal, Tesla and far more
Verify out the organizations earning headlines in midday trading. Eli Lilly — Shares additional 5% just after Eli Lilly, maker of the Mounjaro diabetic issues and pounds decline drug, defeat analysts’ expectations for to start with-quarter modified earnings. The Indianapolis-dependent drugmaker also lifted its complete-year steering for modified earnings and revenue. 3M — Shares jumped […]
Read More
Shares making the major moves premarket: Eli Lilly, 3M, McDonald’s and much more
Look at out the organizations generating headlines in advance of the bell. Eli Lilly — Shares popped approximately 7% right after the maker of the Mounjaro diabetes and body weight decline drug claimed initial-quarter altered earnings of $2.58 for every share, beating the consensus estimate of $2.46, in accordance to LSEG. Eli Lilly also hiked […]
Read More
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss […]
Read More
Why Eli Lilly’s earnings are no sure thing for traders despite obesity drug momentum
Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company’s earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly’s diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The Food and Drug Administration recently reported […]
Read More
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More
Stocks building the largest moves midday: United Airlines, Travelers, Abbott Laboratories and a lot more
Check out out the companies producing headlines in midday buying and selling. United Airways — Shares surged 14% right after the airline posted a narrower-than-expected reduction in the very first quarter. Quarterly profits arrived in at $12.54 billion, topping an LSEG estimate of $12.45 billion. Tourists Companies — The insurance policies stock fell 8% just […]
Read More
Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according […]
Read More